UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

念珠菌性间擦疹

Author
Eva R Parker, MD, FAAD
Section Editors
Robert P Dellavalle, MD, PhD, MSPH
Ted Rosen, MD
Deputy Editor
Abena O Ofori, MD
Translators
李岷, 主任医师

引言

间擦疹是指在相对的两个密切接触或摩擦的皮肤表面(间擦部位)出现的任何感染性或非感染性炎症性疾病。尽管该病可能由包括细菌在内的各种微生物的过度生长引起，但此术语通常是指由念珠菌种皮肤浅表感染所致的疾病过程。念珠菌性间擦疹是有毛发皮肤部位最常见的皮肤念珠菌感染[1]。

本专题中的“间擦疹”术语均是指念珠菌性间擦疹，该病的诊断和治疗将总结在此。由皮肤癣菌感染引起的股癣将单独讨论。 (参见“皮肤癣菌(癣)感染”)

病因和危险因素

皮肤皱褶部位温暖、潮湿的环境是念珠菌生长的理想环境[2]。可增加皮肤摩擦、增加皱褶部位湿度、干扰免疫应答和/或促进真菌过度生长的特定因素能导致感染风险增加[1-7]。

可能增加皮肤摩擦的因素包括：

  • 肥胖
  • 可擦伤皮肤的衣物(尤其是紧身衣)
  • 促进皮肤间摩擦的活动

              

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: 2017-06 . | This topic last updated: 2017-07-14.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Klenk AS, Martin AG, Heffernan MP. Yeast infections: candidiasis, pityriasis (tinea) versicolor. In: Dermatology in General Medicine, Freedberg IM, Eisen AZ, Wolff K, et al (Eds), McGraw-Hill, New York 2003. p.2006.
  2. Yaar M, Gilchrest BA. Aging of skin. In: Fitzpatrick's Dermatology in General Medicine, Freedberg IM, Eisen AZ, Wolff K, et al (Eds), McGraw-Hill, New York 2003. p.1386.
  3. García Hidalgo L. Dermatological complications of obesity. Am J Clin Dermatol 2002; 3:497.
  4. Sobera JO, Elewski BE. Fungal Diseases. In: Dermatology, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Mosby, London 2003. p.1171.
  5. Friedlander SF, Rueda M, Chen BK, Caceres-Rios HW. Fungal, protozoal, and helminthic infections. In: Pediatric Dermatology, Schachner LA, Hansen RC (Eds), Mosby, Edinburgh 2003. p.1093.
  6. Hay RJ. The management of superficial candidiasis. J Am Acad Dermatol 1999; 40:S35.
  7. Jautová J, Baloghová J, Dorko E, et al. Cutaneous candidosis in immunosuppressed patients. Folia Microbiol (Praha) 2001; 46:359.
  8. Hay RJ. Yeast infections. Dermatol Clin 1996; 14:113.
  9. Hay RJ. Antifungal therapy of yeast infections. J Am Acad Dermatol 1994; 31:S6.
  10. Mansour MK, Levitz SM. Interactions of fungi with phagocytes. Curr Opin Microbiol 2002; 5:359.
  11. Odds FC. Pathogenesis of Candida infections. J Am Acad Dermatol 1994; 31:S2.
  12. Hube B, Naglik J. Candida albicans proteinases: resolving the mystery of a gene family. Microbiology 2001; 147:1997.
  13. Schaller M, Schackert C, Korting HC, et al. Invasion of Candida albicans correlates with expression of secreted aspartic proteinases during experimental infection of human epidermis. J Invest Dermatol 2000; 114:712.
  14. Calderone RA. Host-parasite relationships in candidosis. Mycoses 1989; 32 Suppl 2:12.
  15. Costa CR, Jesuíno RS, de Aquino Lemos J, et al. Effects of antifungal agents in sap activity of Candida albicans isolates. Mycopathologia 2010; 169:91.
  16. Bahn YS, Sundstrom P. CAP1, an adenylate cyclase-associated protein gene, regulates bud-hypha transitions, filamentous growth, and cyclic AMP levels and is required for virulence of Candida albicans. J Bacteriol 2001; 183:3211.
  17. Scherwitz C. Ultrastructure of human cutaneous candidosis. J Invest Dermatol 1982; 78:200.
  18. Mukherjee PK, Seshan KR, Leidich SD, et al. Reintroduction of the PLB1 gene into Candida albicans restores virulence in vivo. Microbiology 2001; 147:2585.
  19. Cassone A, Marconi P, Bistoni F. Cell wall of Candida albicans and host response. Crit Rev Microbiol 1987; 15:87.
  20. Beauséjour A, Grenier D, Goulet JP, Deslauriers N. Proteolytic activation of the interleukin-1beta precursor by Candida albicans. Infect Immun 1998; 66:676.
  21. Schaller M, Mailhammer R, Korting HC. Cytokine expression induced by Candida albicans in a model of cutaneous candidosis based on reconstituted human epidermis. J Med Microbiol 2002; 51:672.
  22. Li M, Chen Q, Shen Y, Liu W. Candida albicans phospholipomannan triggers inflammatory responses of human keratinocytes through Toll-like receptor 2. Exp Dermatol 2009; 18:603.
  23. Guitart J, Woodley DT. Intertrigo: a practical approach. Compr Ther 1994; 20:402.
  24. Friedmann PS, Wilkinson M. Occupational dermatoses. In: Dermatology, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Mosby, London 2003. p.251.
  25. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999; 318:1591.
  26. Kauffman CL, Hamet VH, Tahan SR. Fungal infections. In: Textbook of Dermatopathology, Barnhill RL (Ed), McGraw-Hill, New York 2004. p.479.
  27. Chadbourne EB, Zhang S, Gordon MJ, et al. Clinical outcomes in reduction mammaplasty: a systematic review and meta-analysis of published studies. Mayo Clin Proc 2001; 76:503.
  28. Runeman B. Skin interaction with absorbent hygiene products. Clin Dermatol 2008; 26:45.
  29. Gray M. Optimal management of incontinence-associated dermatitis in the elderly. Am J Clin Dermatol 2010; 11:201.
  30. Farage MA, Miller KW, Berardesca E, Maibach HI. Incontinence in the aged: contact dermatitis and other cutaneous consequences. Contact Dermatitis 2007; 57:211.
  31. Phillips RM, Rosen T. Topical antifungal agents. In: Comprehensive Dermatologic Drug Therapy, 3rd ed, Wolverton SE (Ed), W.B. Saunders, Philadelphia 2001. p.497.
  32. McClellan KJ, Wiseman LR, Markham A. Terbinafine. An update of its use in superficial mycoses. Drugs 1999; 58:179.
  33. Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil)--a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol 1989; 14:124.
  34. Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs 2009; 69:339.
  35. Gupta AK, Ryder JE, Cooper EA. Naftifine: a review. J Cutan Med Surg 2008; 12:51.
  36. Gupta AK, Plott T. Ciclopirox: a broad-spectrum antifungal with antibacterial and anti-inflammatory properties. Int J Dermatol 2004; 43 Suppl 1:3.
  37. Evaluation of a new antifungal cream, ciclopirox olamine 1% in the treatment of cutaneous candidosis. Clin Ther 1985; 8:41.
  38. Gupta AK, Bluhm R. Ciclopirox shampoo for treating seborrheic dermatitis. Skin Therapy Lett 2004; 9:4.
  39. Sundaram SV, Srinivas CR, Thirumurthy M. Candidal intertrigo: treatment with filter paper soaked in Castellani's paint. Indian J Dermatol Venereol Leprol 2006; 72:386.
  40. Leyden JJ. Corn starch, Candida albicans, and diaper rash. Pediatr Dermatol 1984; 1:322.
  41. Cramer DW, Liberman RF, Titus-Ernstoff L, et al. Genital talc exposure and risk of ovarian cancer. Int J Cancer 1999; 81:351.
  42. Railan D, Wilson JK, Feldman SR, Fleischer AB. Pediatricians who prescribe clotrimazole-betamethasone diproprionate (Lotrisone) often utilize it in inappropriate settings regardless of their knowledge of the drug's potency. Dermatol Online J 2002; 8:3.
  43. Burnett BP, Mitchell CM. Antimicrobial activity of iodoquinol 1%-hydrocortisone acetate 2% gel against ciclopirox and clotrimazole. Cutis 2008; 82:273.
  44. Stengel F, Robles-Soto M, Galimberti R, Suchil P. Fluconazole versus ketoconazole in the treatment of dermatophytoses and cutaneous candidiasis. Int J Dermatol 1994; 33:726.
  45. Nozickova M, Koudelkova V, Kulikova Z, et al. A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis. Int J Dermatol 1998; 37:703.
  46. Coldiron BM, Manders SM. Persistent Candida intertrigo treated with fluconazole. Arch Dermatol 1991; 127:165.
  47. Gupta AK. Systemic antifungal agents. In: Comprehensive Dermatologic Drug Therapy, Wolverton SE (Ed), W.B. Saunders, Philadelphia 2001. p.55.
  48. Piérard GE, Arrese JE, De Doncker P. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol 1995; 32:429.
  49. Daning L, Dinguo Z, Wenwei S, Peihong J. Extensive skin candidosis in an adult: effective treatment with itraconazole. Mycoses 1998; 41:219.
  50. Del Rosso JQ, Zellis S, Gupta AK. Itraconazole in the treatment of superficial cutaneous and mucosal Candida infections. J Am Osteopath Assoc 1998; 98:497.
  51. American Academy of Pediatrics. Antimicrobial agents and related therapy. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.737.
  52. www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001855.jsp&mid=WC0b01ac058004d5c1 (Accessed on July 26, 2013).
  53. www.fda.gov/Drugs/DrugSafety/ucm362415.htm (Accessed on July 26, 2013).
  54. Roberts DT, Rishardson MD, Dwyer PK, et al. Terbinafine in chronic paronychia and Candida onychomycosis. J Dermatol Treat 1992; 2(Suppl 1):39.
  55. Segal R, Kritzman A, Cividalli L, et al. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol 1996; 35:958.
  56. Ryder NS, Wagner S, Leitner I. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts. Antimicrob Agents Chemother 1998; 42:1057.
  57. Katz HI, Gupta AK. Oral antifungal drug interactions: a mechanistic approach to understanding their cause. Dermatol Clin 2003; 21:543.
  58. Chapman MS, Brown JM, Linowski GJ. 0.1% tacrolimus ointment for the treatment of intertrigo. Arch Dermatol 2005; 141:787.
  59. Habif T. Clinical Dermatology, 4th ed, Mosby, Philadelphia 2004. p.447.